Assertio Therapeutics, Inc. (ASRT): Price and Financial Metrics

Assertio Therapeutics, Inc. (ASRT): $6.20

0.00 (0.00%)

POWR Rating

Component Grades








Add ASRT to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals




#54 of 167

in industry

ASRT Price/Volume Stats

Current price $6.20 52-week high $8.01
Prev. close $6.20 52-week low $2.07
Day low $6.08 Volume 399,632
Day high $6.24 Avg. volume 2,008,712
50-day MA $6.32 Dividend yield N/A
200-day MA $4.28 Market Cap 345.34M

ASRT Stock Price Chart Interactive Chart >


  • Value is the dimension where ASRT ranks best; there it ranks ahead of 97.27% of US stocks.
  • The strongest trend for ASRT is in Sentiment, which has been heading down over the past 179 days.
  • ASRT ranks lowest in Stability; there it ranks in the 3rd percentile.

ASRT Stock Summary

  • With a price/earnings ratio of 3.77, ASSERTIO HOLDINGS INC P/E ratio is greater than that of about just 7.37% of stocks in our set with positive earnings.
  • With a year-over-year growth in debt of -47.47%, ASSERTIO HOLDINGS INC's debt growth rate surpasses just 6.17% of about US stocks.
  • In terms of volatility of its share price, ASRT is more volatile than 89.45% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ASSERTIO HOLDINGS INC are BKSY, AMK, CUEN, GURE, and MEC.
  • Visit ASRT's SEC page to see the company's official filings. To visit the company's web site, go to

ASRT Valuation Summary

  • ASRT's price/sales ratio is 2.3; this is 4.55% higher than that of the median Healthcare stock.
  • ASRT's price/earnings ratio has moved up 8.7 over the prior 243 months.

Below are key valuation metrics over time for ASRT.

Stock Date P/S P/B P/E EV/EBIT
ASRT 2023-05-23 2.3 1.5 3.8 15.0
ASRT 2023-05-22 2.4 1.6 4.0 16.0
ASRT 2023-05-19 2.5 1.6 4.2 16.7
ASRT 2023-05-18 2.4 1.6 4.1 16.1
ASRT 2023-05-17 2.4 1.6 4.1 16.2
ASRT 2023-05-16 2.3 1.5 3.9 15.5

ASRT Growth Metrics

    Its year over year net income to common stockholders growth rate is now at 104.99%.
  • The 3 year net income to common stockholders growth rate now stands at 128.87%.
  • Its 2 year net income to common stockholders growth rate is now at 102%.
Over the past 49 months, ASRT's revenue has gone down $224,369,000.

The table below shows ASRT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 139.209 56.032 25.678
2022-06-30 130.469 50.641 25.241
2022-03-31 120.711 37.175 3.238
2021-12-31 111.014 5.523 -1.281
2021-09-30 107.86 -4.59 -30.241
2021-06-30 116.953 -23.675 -44.5

ASRT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ASRT has a Quality Grade of C, ranking ahead of 35.61% of graded US stocks.
  • ASRT's asset turnover comes in at 0.367 -- ranking 129th of 680 Pharmaceutical Products stocks.
  • NOVN, ARWR, and RIOT are the stocks whose asset turnover ratios are most correlated with ASRT.

The table below shows ASRT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.367 0.819 -1.136
2021-03-31 0.343 0.800 -1.673
2020-12-31 0.354 0.813 -0.761
2020-09-30 0.380 0.884 -1.944
2020-06-30 0.337 0.927 -1.098
2020-03-31 0.332 0.957 -0.485

ASRT Price Target

For more insight on analysts targets of ASRT, see our ASRT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.20 Average Broker Recommendation 1.5 (Moderate Buy)

Assertio Therapeutics, Inc. (ASRT) Company Bio

Assertio Therapeutics, Inc. (formerly DepoMed) develops products for pain and other central nervous system conditions in the United States. The company was founded in 1995 and is focused in Newark, California.

ASRT Latest News Stream

Event/Time News Detail
Loading, please wait...

ASRT Latest Social Stream

Loading social stream, please wait...

View Full ASRT Social Stream

Latest ASRT News From Around the Web

Below are the latest news stories about ASSERTIO HOLDINGS INC that investors may wish to consider to help them evaluate ASRT as an investment opportunity.

Does Assertio Holdings (NASDAQ:ASRT) Deserve A Spot On Your Watchlist?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Yahoo | May 26, 2023

Assertio Holdings First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags

Assertio Holdings ( NASDAQ:ASRT ) First Quarter 2023 Results Key Financial Results Revenue: US$42.5m (up 16% from 1Q...

Yahoo | May 10, 2023

Q1 2023 Assertio Holdings Inc Earnings Call

Q1 2023 Assertio Holdings Inc Earnings Call

Yahoo | May 10, 2023

Assertio Reports First Quarter 2023 Financial Results, Raises Full Year 2023 Outlook

Net Product Sales Increase 18% Year-Over-Year Raises Full Year Outlook to Net Product Sales of $157 to $167 Million, Adjusted EBITDA $90 to $98 Million To Acquire Spectrum Pharmaceuticals in All Stock and CVR Transaction, Expected to be Significantly Accretive to Adjusted EPS and Operating Cash Flow in 2024 LAKE FOREST, Ill., May 09, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products t

Yahoo | May 9, 2023

Assertio Holdings, Inc.'s (NASDAQ:ASRT) largest shareholders are individual investors with 58% ownership, institutions own 40%

Key Insights The considerable ownership by individual investors in Assertio Holdings indicates that they collectively...

Yahoo | May 9, 2023

Read More 'ASRT' Stories Here

ASRT Price Returns

1-mo 0.81%
3-mo 4.03%
6-mo 67.57%
1-year 100.00%
3-year 55.72%
5-year -76.19%
YTD 44.19%
2022 97.25%
2021 52.40%
2020 -71.39%
2019 -65.37%
2018 -55.16%

Continue Researching ASRT

Here are a few links from around the web to help you further your research on Assertio Therapeutics Inc's stock as an investment opportunity:

Assertio Therapeutics Inc (ASRT) Stock Price | Nasdaq
Assertio Therapeutics Inc (ASRT) Stock Quote, History and News - Yahoo Finance
Assertio Therapeutics Inc (ASRT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!